Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.

Updated versions of best-selling drugs may mitigate some of the impact of patent cliff losses, but strategy is key in a ...

As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate ...

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaApproval based on global phase 3 program ...

Regeneron has had its hands full this year contending with regulatory setbacks, Amgen's marketed Eylea biosimilar and Roche's hard-charging ophthalmology rival Vabysmo. Next year, the biosimilar ...

Bayer Aktiengesellschaft remains deeply undervalued despite ongoing operational and litigation headwinds, supporting a bullish stance. Q3/25 results were weak, but technicals and intrinsic value ...

Alvotech (ALVO) and Teva Pharmaceuticals (TEVA) have reached a settlement and license agreement with Regeneron Pharmaceuticals (REGN) concerning the launch of AVT06, Alvotech’s proposed biosimilar to ...

The proposed aflibercept biosimilar is intended to treat ophthalmic disorders. This FDA submission follows the licensing agreement under which Fresenius Kabi will exclusively commercialize the ...

REYKJAVIK, Iceland and TEL AVIV, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

(RTTNews) - Alvotech (ALVO) and Teva Pharmaceutical Industries Ltd. (TEVA) have secured a U.S. license entry date for AVT06, the proposed biosimilar to Regeneron's Eylea, setting the stage for a ...

At the end of July, and before the company’s quarterly earnings report coming on Aug. 6, Bayer announced it has allocated an additional $1.37 billion to its efforts around glyphosate litigation. The ...

Heading into the second half of their 2025 financial year, Bayer leaders echo positive comments surrounding the company’s crop science division. What has them bullish? First, Bayer is optimistic the ...